NEUROCRINE BIOSCIENCES INC (1NBIX.MI) Fundamental Analysis & Valuation

BIT:1NBIX • US64125C1099

Current stock price

111.55 EUR
-20 (-15.2%)
Last:

This 1NBIX.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. 1NBIX.MI Profitability Analysis

1.1 Basic Checks

  • 1NBIX had positive earnings in the past year.
  • In the past year 1NBIX had a positive cash flow from operations.
  • 1NBIX had positive earnings in each of the past 5 years.
  • Each year in the past 5 years 1NBIX had a positive operating cash flow.
1NBIX.MI Yearly Net Income VS EBIT VS OCF VS FCF1NBIX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 10.03%, 1NBIX belongs to the top of the industry, outperforming 85.54% of the companies in the same industry.
  • The Return On Equity of 1NBIX (14.25%) is better than 83.13% of its industry peers.
  • 1NBIX has a better Return On Invested Capital (11.10%) than 81.93% of its industry peers.
  • 1NBIX had an Average Return On Invested Capital over the past 3 years of 11.40%. This is in line with the industry average of 10.61%.
Industry RankSector Rank
ROA 10.03%
ROE 14.25%
ROIC 11.1%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1NBIX.MI Yearly ROA, ROE, ROIC1NBIX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • The Profit Margin of 1NBIX (15.95%) is better than 78.31% of its industry peers.
  • In the last couple of years the Profit Margin of 1NBIX has grown nicely.
  • 1NBIX's Operating Margin of 20.64% is fine compared to the rest of the industry. 1NBIX outperforms 77.11% of its industry peers.
  • In the last couple of years the Operating Margin of 1NBIX has declined.
  • 1NBIX has a Gross Margin of 98.37%. This is amongst the best in the industry. 1NBIX outperforms 96.39% of its industry peers.
  • 1NBIX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.64%
PM (TTM) 15.95%
GM 98.37%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
1NBIX.MI Yearly Profit, Operating, Gross Margins1NBIX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. 1NBIX.MI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1NBIX is creating some value.
  • Compared to 1 year ago, 1NBIX has more shares outstanding
  • 1NBIX has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for 1NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1NBIX.MI Yearly Shares Outstanding1NBIX.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
1NBIX.MI Yearly Total Debt VS Total Assets1NBIX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • 1NBIX has an Altman-Z score of 7.69. This indicates that 1NBIX is financially healthy and has little risk of bankruptcy at the moment.
  • 1NBIX's Altman-Z score of 7.69 is amongst the best of the industry. 1NBIX outperforms 81.93% of its industry peers.
  • There is no outstanding debt for 1NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.69
ROIC/WACC1.25
WACC8.86%
1NBIX.MI Yearly LT Debt VS Equity VS FCF1NBIX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 3.38 indicates that 1NBIX has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 3.38, 1NBIX is doing good in the industry, outperforming 69.88% of the companies in the same industry.
  • 1NBIX has a Quick Ratio of 3.27. This indicates that 1NBIX is financially healthy and has no problem in meeting its short term obligations.
  • 1NBIX has a better Quick ratio (3.27) than 73.49% of its industry peers.
Industry RankSector Rank
Current Ratio 3.38
Quick Ratio 3.27
1NBIX.MI Yearly Current Assets VS Current Liabilites1NBIX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. 1NBIX.MI Growth Analysis

3.1 Past

  • 1NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.06%, which is quite good.
  • Measured over the past years, 1NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 58.39% on average per year.
  • The Revenue has grown by 19.61% in the past year. This is quite good.
  • Measured over the past years, 1NBIX shows a very strong growth in Revenue. The Revenue has been growing by 24.48% on average per year.
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%

3.2 Future

  • 1NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.05% yearly.
  • 1NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.42% yearly.
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y35.05%
Revenue Next Year21.48%
Revenue Next 2Y19.96%
Revenue Next 3Y16.2%
Revenue Next 5Y12.42%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
1NBIX.MI Yearly Revenue VS Estimates1NBIX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
1NBIX.MI Yearly EPS VS Estimates1NBIX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

6

4. 1NBIX.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 30.81, which means the current valuation is very expensive for 1NBIX.
  • 1NBIX's Price/Earnings ratio is a bit cheaper when compared to the industry. 1NBIX is cheaper than 75.90% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 24.88, 1NBIX is valued a bit more expensive.
  • 1NBIX is valuated rather expensively with a Price/Forward Earnings ratio of 17.88.
  • 87.95% of the companies in the same industry are more expensive than 1NBIX, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of 1NBIX to the average of the S&P500 Index (22.19), we can say 1NBIX is valued inline with the index average.
Industry RankSector Rank
PE 30.81
Fwd PE 17.88
1NBIX.MI Price Earnings VS Forward Price Earnings1NBIX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1NBIX indicates a somewhat cheap valuation: 1NBIX is cheaper than 78.31% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, 1NBIX is valued cheaply inside the industry as 86.75% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 21.65
EV/EBITDA 18.78
1NBIX.MI Per share data1NBIX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • 1NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • 1NBIX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as 1NBIX's earnings are expected to grow with 37.96% in the coming years.
PEG (NY)0.55
PEG (5Y)0.53
EPS Next 2Y47.98%
EPS Next 3Y37.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1NBIX.MI Dividend Analysis

5.1 Amount

  • No dividends for 1NBIX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1NBIX.MI Fundamentals: All Metrics, Ratios and Statistics

NEUROCRINE BIOSCIENCES INC

BIT:1NBIX (3/2/2026, 7:00:00 PM)

111.55

-20 (-15.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)05-04
Inst Owners100.41%
Inst Owner ChangeN/A
Ins Owners1.12%
Ins Owner ChangeN/A
Market Cap11.20B
Revenue(TTM)2.68B
Net Income(TTM)428.00M
Analysts84.44
Price Target151.24 (35.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)0%
PT rev (3m)4.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.56%
EPS NY rev (1m)0%
EPS NY rev (3m)1.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 30.81
Fwd PE 17.88
P/S 4.79
P/FCF 21.65
P/OCF 20.17
P/B 4.28
P/tB 4.33
EV/EBITDA 18.78
EPS(TTM)3.62
EY3.25%
EPS(NY)6.24
Fwd EY5.59%
FCF(TTM)5.15
FCFY4.62%
OCF(TTM)5.53
OCFY4.96%
SpS23.3
BVpS26.09
TBVpS25.78
PEG (NY)0.55
PEG (5Y)0.53
Graham Number46.1
Profitability
Industry RankSector Rank
ROA 10.03%
ROE 14.25%
ROCE 15.26%
ROIC 11.1%
ROICexc 16.02%
ROICexgc 16.25%
OM 20.64%
PM (TTM) 15.95%
GM 98.37%
FCFM 22.11%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 147.14%
Cap/Sales 1.63%
Interest Coverage 250
Cash Conversion 109.17%
Profit Quality 138.57%
Current Ratio 3.38
Quick Ratio 3.27
Altman-Z 7.69
F-Score5
WACC8.86%
ROIC/WACC1.25
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y35.05%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
Revenue Next Year21.48%
Revenue Next 2Y19.96%
Revenue Next 3Y16.2%
Revenue Next 5Y12.42%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year4.42%
EBIT Next 3Y19.54%
EBIT Next 5Y19.04%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%

NEUROCRINE BIOSCIENCES INC / 1NBIX.MI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NEUROCRINE BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 7 / 10 to 1NBIX.MI.


What is the valuation status for 1NBIX stock?

ChartMill assigns a valuation rating of 7 / 10 to NEUROCRINE BIOSCIENCES INC (1NBIX.MI). This can be considered as Undervalued.


How profitable is NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?

NEUROCRINE BIOSCIENCES INC (1NBIX.MI) has a profitability rating of 7 / 10.


What is the financial health of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?

The financial health rating of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is 8 / 10.


What is the expected EPS growth for NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?

The Earnings per Share (EPS) of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is expected to grow by 55.94% in the next year.